Table 1.
The demographic and clinical characteristics of patients in training and validation cohorts
| Variable | Training cohort (n=156) |
Validation cohort (n=104) |
Total (n=260) |
p value |
|---|---|---|---|---|
| Age, median (IQR), y | 58±13.8 | 57±12.1 | 57±13.1 | 0.972 |
| Gender Male Female |
64.1% (100/156) 35.9% (56/156) |
67.3% (70/104) 32.7% (34/104) |
68.0% (170/260) 34.6% (90/260) |
0.596 |
| G grade G1 G2 G3 |
31.4% (49/156) 16.0% (14/156) 52.6% (48/156) |
34.6% (36/104) 19.2% (20/104) 46.2% (48/104) |
32.7% (85/260) 17.3% (45/260) 50.0% (130/260) |
0.397 |
| Ki-67 index (%) <3 3-20 >20 |
35.9% (56/156) 27.6% (43/156) 36.5% (57/156) |
34.6% (38/104) 19.2% (25/104) 39.4% (41/104) |
36.2% (94/260) 26.2% (68/260) 37.7% (98/260) |
0.802 |
| Mitoses (/10HPF) <2 2-20 >20 |
42.3% (66/156) 26.9% (42/156) 30.8% (48/156) |
45.2% (47/104) 34.6% (36/104) 20.2% (21/104) |
43.5% (113260) 30.0% (78/260) 26.5% (69/260) |
0.137 |
| T stage (pT) T1 T2 T3 T4 |
24.7% (37/150) 24.0% (36/150) 26.7% (40/150) 24.7% (37/150) |
28.8% (30/104) 22.1% (23/104) 31.7% (33/104) 17.3% (18/104) |
25.8% (67/254) 22.7% (59/254) 28.1% (73/254) 21.2% (55/254) |
0.460 |
| N stage (pN) N0 N1 |
68.6% (107/156) 31.4% (49/156) |
64.4% (67/104) 35.6% (37/104) |
66.9% (174/260) 33.1% (86/260) |
0.484 |
| Distant metastasis No Yes |
78.2% (122/156) 21.8% (34/156) |
88.5% (92/104) 11.5% (12/104) |
82.3% (214/260) 17.7% (46/260) |
0.034 |
| Tumor size <2cm ≥2cm |
59.0% (92/156) 41.0% (64/156) |
62.5% (65/104) 37.5% (39/104) |
60.4% (157/260) 39.6% (103/260) |
0.597 |
| Blood NLR ≤2.40 >2.40 |
67.9% (106/156) 32.1% (50/156) |
64.4% (67/104) 35.6% (37/104) |
66.5% (173/260) 33.5% (87/260) |
0.555 |
| Serum CEA/CA19-9 Normal Elevated |
75.0 % (117/156) 25.0% (39/156) |
78.8% (82/104) 21.2% (22/104) |
76.5% (199/260) 23.5% (61/260) |
0.473 |
| Operation Curative Palliative (R1/R2) No operation |
74.4% (116/156) 19.9% (31/156) 5.8% (9/156) |
83.7% (87/104) 10.6% (11/104) 5.8 (6/104) |
78.1% (203/260) 16.2% (42/260) 5.8% (15/260) |
0.133 |
| Status Alive Dead |
61.5% (96/156) 38.5% (60/156) |
63.5% (66/104) 36.5% (38/104) |
62.3% (162/260) 37.7% (98/260) |
0.754 |
| Relapse free survival, months, median (95% CI) | 36.7 (35.2-38.2) (n=116) |
35.0 (33.4-36.6) (n=87) |
36.0 (34.9-37.1) (n=203) |
|
| Follow-up, months, median (95% CI) | 48.4 (46.8-50.0) | 51.0 (49.2-52.8) | 49.6 (48.4-50.8) | 0.409 |
CI confidence interval, IQR interquartile range